Pandemic influenza vaccine: characterization of A/California/07/2009 (H1N1) recombinant hemagglutinin protein and insights into H1N1 antigen stability

Table 3 Potency by SRID for licensed monovalent H1N1 vaccines calculated using different antisera and reference antigens

Vaccine	SRID reference antigen	Reference antigen source	Potency according to SRID (μg/mL)
			SRID antiserum source
			CBER	NIBSC	PSC
Commercial Vaccine 1 (Novartis)	X-181	CBER	30.5	17.9	17.3
	X-181	NIBSC	36.6	24.4	22.2
	X-179A	CBER	71.4	41.0	28.4
	X-179A	NIBSC	88.1	54.2	36.8
Commercial Vaccine 2 (Sanofi Pasteur)	X-181	CBER	15.5	14.6	17.4
	X-181	NIBSC	19.1	20.3	22.6
	X-179A	CBER	47.1	33.6	29.3
		NIBSC	59.1	41.8	38.8

SRID potency values are listed in μg/mL. Results were calculated using X-181 or X-179A reference antigens obtained from CBER or NIBSC, using SRID gels prepared with sheep antiserum obtained from NIBSC against egg-derived A/California/07/2009 HA, sheep antiserum obtained from CBER against E. coli-expressed recombinant HA1 fragment, or rabbit antiserum produced by Protein Sciences Corporation (PSC) against purified A/California/07/2009 rHA.

ISSN: 1472-6750